Publikationen 1999
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study
Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, Telenti A, Vernazza P L, Bernasconi E, Sudre P
JAIDS 1999;21:114-119
Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study
Schlegel M, Osterwalder J J, Galeazzi R L, Vernazza P L
BMJ 1999;319:352-353
HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia
Thomas Wendland, Hansjakob Furrer, Pietro L. Vernazza, Karin Frutig, Anna Christen, Lukas Matter, Raffaele Malinverni and Werner J. Pichler
AIDS 1999;13 / 14:1857-1862
Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study
Junghans C, Low N, Chan P, Witschi A, Vernazza PL, Egger M
AIDS 1999;13:2547-2554
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, Telenti A, Vernazza PL, Rickenbach M, Flepp M, Malinverni R
NEJM 1999;340 / 17:1301-1306
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza PL, Sudre P, Flepp M, Furrer H, Francioli P, Weber R
Lancet 1999;353:863-868
Sexual transmission of HIV: infectiousness and prevention
Vernazza PL, Eron JJ, Fiscus SA, Cohen MS
AIDS 1999;13 / 2:155-166
Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants
Ping LH, Nelson JA, Hoffman IF, Schock J, Lamers SL, Goodman M, Vernazza PL, Kazembe P, Maida M, Zimba D, Goodenow MM, Eron JJ Jr, Fiscus SA, Cohen MS, Swanstrom R
J Virol 1999;37 / 8:6271-6281
HIV 1999: Suppression um jeden Preis?
Vernazza PL
SMW 1999;129:2010-2013
Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study
Zinkernagel C, Ledergerber B, Battegay M, Cone RW, Vernazza PL, Hirschel B, Opravil M
AIDS 1999; 13/12:1587-1589
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study
Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A
JAMA 1999;282/23: 2220 – 2226
